R 85355

Drug Profile

R 85355

Latest Information Update: 28 Sep 1998

Price : $50

At a glance

  • Originator Janssen L.P.
  • Class Antiallergics; Antiasthmatics
  • Mechanism of Action 5-lipoxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Asthma; Psoriasis

Most Recent Events

  • 28 Sep 1998 No-Development-Reported for Psoriasis in Netherlands (Topical)
  • 27 Aug 1997 Investigation in Psoriasis in Netherlands (Topical)
  • 27 Aug 1997 No-Development-Reported for Asthma in Belgium (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top